There were two multicenter, single-arm studies (studies A and B) in which patients with ALK-positive NSCLC received crizotinib 250 mg twice daily (Camidge et al., 2011; Crino et al., 2011; Kwak et al., 2010). The gene discussed is ALK; the disease is non-small cell lung carcinoma.